Page 3 - Thomas Theuringer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Simplified and accelerated research workflow including high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis // Workflow enables diverse microbiome research applications, including gut health, soil microbiology, and antibiotic resistance, maximizing DNA diversity and minimizing bias // Expanding growing portfolio of QIAGEN microbiome solutions, covering every aspect of the scientific workflowVenlo, the Netherlands, Nov. 06,

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Venlo, the Netherlands, Oct. 30, 2023 -- QIAGEN announced results for the third quarter and first nine months of 2023. Net sales results of $470 million at constant exchange rates for Q3 2023...

Q3 2023: Net sales of $476 million (-5% at actual rates, -6% at constant exchange rates, CER); diluted EPS of $0.34 and adjusted diluted EPS of $0.50 // Net sales at CER of $470 million ahead of outlook for at least $465 million CER and adjusted diluted EPS of $0.50 CER ahead of outlook for at least $0.48 CER // 5% CER sales growth in non-COVID portfolio to $442 million, supported by higher sales from instruments as well as recurring consumables and related revenues // 9M 2023: 8% CER sales grow

Venlo, the Netherlands, Oct. 04, 2023 -- QIAGEN today announced the launch of its QuantiFERON-EBV RUO assay. Epstein-Barr virus , or human herpes virus 4, is estimated in various epidemiological...